Patent
The invention relates to a bacterial strain of species Faecalibacterium prausnitzii deposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.
1. Method for the treatment of an inflammatory gastrointestinal disease in an individual comprising administering to the said individual a bacterial strain of the species Faecalibacterium prausnitzii deposited with the CNCM under accession number CNCM 1-4573.
2. The method as claimed in claim 1 , characterized in that the individual is a mammal.
3. The method as claimed in claim 1 , characterized in that the individual is a human being.
4. The method as claimed in claim 1 , characterized in that the inflammatory gastrointestinal disease is an inflammatory bowel disease.
5. The method as claimed in claim 1 , characterized in that the inflammatory gastrointestinal disease is a colonic inflammatory bowel disease.
6. The method as claimed in claim 5 , characterized in that the colonic inflammatory bowel disease is chosen from the group consisting of Crohn's disease, ulcerative colitis and pouchitis.
7. The method as claimed in claim 5 , characterized in that the colonic inflammatory bowel disease is chosen from the group consisting of Crohn's disease and ulcerative colitis.
8. The method as claimed in claim 1 , characterized in that the bacterial strain is included in a composition comprising a physiologically acceptable medium.
9. The method as claimed in claim 1 , characterized in that the bacterial strain is included in an oral composition.
10. The method as claimed in claim 1 , characterized in that the bacterial strain is included in a food supplement.
11. The method as claimed in claim 8 , characterized in that the composition is suitable for the administration of a daily dose representing from 10 7 to 10 11 colony-forming units (cfu) as a medicament.
12. The method as claimed in claim 8 , characterized in that the composition is for oral administration and is chosen from the group consisting of a food product, a beverage, a pharmaceutical product, a nutraceutical, a food additive, a food supplement and a milk product.
13. The method as claimed in claim 12 , characterized in that the composition is for oral administration and is a food supplement.
14. The method as claimed in claim 9 , characterized in that the composition is suitable for the administration of a daily dose representing from 10 7 to 10 11 colony-forming units (cfu) as a medicament.
15. The method as claimed in claim 10 , characterized in that the composition is suitable for the administration of a daily dose representing from 10 7 to 10 11 colony-forming units (cfu) as a medicament.